Edition:
India

MiMedx Group Inc (MDXG.OQ)

MDXG.OQ on NASDAQ Stock Exchange Capital Market

8.95USD
2:06am IST
Change (% chg)

$-5.52 (-38.15%)
Prev Close
$14.47
Open
$9.90
Day's High
$10.40
Day's Low
$8.65
Volume
4,003,251
Avg. Vol
651,451
52-wk High
$18.24
52-wk Low
$7.70

Select another date:

Thu, Jan 18 2018

BRIEF-Mimedx Comments On Magistrate Recommendation In Co's Lawsuit Against Short Sellers

* MIMEDX COMMENTS ON MAGISTRATE RECOMMENDATION IN THE COMPANY'S LAWSUIT AGAINST SHORT SELLERS

BRIEF-Mimedx Announces First Patients Have Been Enrolled In The Phase 3 Clinical Trial Of Amniofix

* MIMEDX ANNOUNCES FIRST PATIENTS HAVE BEEN ENROLLED IN THE PHASE 3 CLINICAL TRIAL OF AMNIOFIX® INJECTABLE IN PATIENTS WITH RECALCITRANT PLANTAR FASCIITIS PAIN

BRIEF-Mimedx Settles Patent Infringement Lawsuit

* MIMEDX - SUCCESSFULLY SETTLED CO'S PATENT INFRINGEMENT LAWSUIT AGAINST MUSCULOSKELETAL TRANSPLANT FOUNDATION, MEDLINE INDUSTRIES, LIVENTA BIOSCIENCE

BRIEF-MiMedx Agrees To Lawsuit Settlement With Former Employee

* MIMEDX GROUP INC - COMPANY HAS AGREED TO A CONFIDENTIAL LAWSUIT SETTLEMENT FROM ONE FORMER EMPLOYEE

BRIEF-MiMedx Forecasts 2018 Revenue To Be In Range Of $383 Mln To $387 Mln

* MIMEDX FORECASTS 2018 REVENUE TO BE IN THE RANGE OF $383 MILLION TO $387 MILLION

BRIEF-MiMedx Says It Expects To Exceed Top End Of Q4 Revenue Guidance Of $88 Mln

* MIMEDX ANNOUNCES EXPECTATION TO EXCEED TOP END OF FOURTH QUARTER REVENUE GUIDANCE OF $88 MILLION

BRIEF-Mimedx provides update on its reimbursement coverage

* Mimedx Group Inc - ‍provided a reimbursement update in light of FDA final and draft guidance documents related to human tissue​

BRIEF-MiMedx Group sees FY 2017 revenue $320.6 million to $321.6 million

* MiMedx Group Inc - ‍reiterates Q4 and full year 2017 guidance​

BRIEF-MiMedx announces Q3 2017 results

* MiMedx announces record results for third quarter of 2017 and raises full year revenue guidance

BRIEF-Mimedx Group Inc preliminary Q3 revenue $84.6 million

* Announces third quarter revenues of $84.6 million exceeds guidance by more than 5 percent

Select another date: